Nintedanib Demonstrates Promise in LUME-Lung-1 Trial in Patients With Advanced or Recurrent NSCLC
A new oral angiogenesis inhibitor for the treatment of lung cancer could be edging closer to the market: Approval application for nintedanib (Boehringer Ingelheim) has been filed in Europe and is being prepared for the United States.
The data for nintedanib come from the phase 3 trial known as LUME-Lung-1, recently published in the Lancet Oncology.
The data were also presented in a poster and discussed here at the European Lung Cancer Conference (ELCC) 2014 by principal investigator, Martin Reck, MD, PhD, head of thoracic oncology at the Lungen Clinic, Grosshansdorf, Germany.
The trial was conducted in 1314 previously treated patients with stage 3B or 4 or recurrent non-small cell lung cancer (NSCLC), who were given docetaxel as second-line therapy. Adding nintedanib significantly improved the progression-free survival to 3.4 months vs 2.7 months with docetaxel alone (hazard ratio [HR], 0.79; P = .0019).
The improvement in overall survival (OS) for all participants did not reach significance (10.1 vs 9.1 months; P = .27).
Read the complete news here: http://bit.ly/1ffqvtT